RATIONALE: Antibiotic inhalation has become widely accepted as a standard treatment for cystic fibrosis (CF) airway infection. We assessed the prevalence and context of inhaled antibiotic use in the North American CF population. Our working hypothesis was that a shift from acute to chronic use of inhaled antibiotics has coincided with increased prevalence of use among CF patients. METHODS: Descriptive statistics were collected for 30,833 patients enrolled in the Epidemiologic Study of CF (ESCF) during 1996 through 2005. A multivariate analysis was performed on data from a subgroup of 18,021 patients enrolled in ESCF during 2003 through 2005. RESULTS: The prevalence of inhaled antibiotic use in the North American CF population increased during 1996 through 2005 due to increased chronic use, while acute use to treat pulmonary exacerbations decreased. In 2005, 50% of CF patients used inhaled tobramycin and 9% used inhaled colistin chronically; most of the latter used both agents concurrently. Airway obstruction severity and airway infection status were predictors of inhaled antibiotic use. CONCLUSIONS: Increased chronic use and decreased acute use of inhaled antibiotics presumably reflect a shift toward more proactive management of airway infections in the North American CF population. The effects of these usage patterns on long-term clinical outcomes and emergence of antibiotic-resistant Pseudomonas aeruginosa strains warrant further study. (c) 2008 Wiley-Liss, Inc.
RATIONALE: Antibiotic inhalation has become widely accepted as a standard treatment for cystic fibrosis (CF) airway infection. We assessed the prevalence and context of inhaled antibiotic use in the North American CF population. Our working hypothesis was that a shift from acute to chronic use of inhaled antibiotics has coincided with increased prevalence of use among CF patients. METHODS: Descriptive statistics were collected for 30,833 patients enrolled in the Epidemiologic Study of CF (ESCF) during 1996 through 2005. A multivariate analysis was performed on data from a subgroup of 18,021 patients enrolled in ESCF during 2003 through 2005. RESULTS: The prevalence of inhaled antibiotic use in the North American CF population increased during 1996 through 2005 due to increased chronic use, while acute use to treat pulmonary exacerbations decreased. In 2005, 50% of CF patients used inhaled tobramycin and 9% used inhaled colistin chronically; most of the latter used both agents concurrently. Airway obstruction severity and airway infection status were predictors of inhaled antibiotic use. CONCLUSIONS: Increased chronic use and decreased acute use of inhaled antibiotics presumably reflect a shift toward more proactive management of airway infections in the North American CF population. The effects of these usage patterns on long-term clinical outcomes and emergence of antibiotic-resistant Pseudomonas aeruginosa strains warrant further study. (c) 2008 Wiley-Liss, Inc.
Authors: Samuel M Moskowitz; Elizabeth Garber; Yunhua Chen; Sarah A Clock; Setareh Tabibi; Amanda K Miller; Michael Doctor; Lisa Saiman Journal: J Antimicrob Chemother Date: 2010-04-29 Impact factor: 5.790
Authors: Samuel M Moskowitz; Mark K Brannon; Nandini Dasgupta; Miyuki Pier; Nicole Sgambati; Amanda K Miller; Sara E Selgrade; Samuel I Miller; Miles Denton; Steven P Conway; Helle K Johansen; Niels Høiby Journal: Antimicrob Agents Chemother Date: 2011-11-21 Impact factor: 5.191
Authors: Amanda K Miller; Mark K Brannon; Laurel Stevens; Helle Krogh Johansen; Sara E Selgrade; Samuel I Miller; Niels Høiby; Samuel M Moskowitz Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191
Authors: Alina D Gutu; Nicole Sgambati; Pnina Strasbourger; Mark K Brannon; Michael A Jacobs; Eric Haugen; Rajinder K Kaul; Helle Krogh Johansen; Niels Høiby; Samuel M Moskowitz Journal: Antimicrob Agents Chemother Date: 2013-03-04 Impact factor: 5.191